Welcome to the MercyOne Des Moines Medical Center Institutional Review Board page.
The IRB is a committee, formally designated by MercyOne Des Moines Medical Center, to review, approve the initiation of, and conduct ongoing review of investigational research involving human subjects.
The purpose of the IRB is to ensure that no investigational research done under the jurisdiction or premises of MercyOne Des Moines Medical Center shall expose persons who participate as subjects to unreasonable risks to their health, general well-being, or privacy. It is the policy of MercyOne Des Moines Medical Center that in all research- related activities involving the participation of human subjects that the:
Additional Online Resources for Patients:
To access the IRB's Policies & Procedures, click: MercyOne Des Moines IRB Policies & Procedures
The Institutional Review Board (IRB) serves all research sites, clinical sites, and students who are doing research at MercyOne Des Moines Medical Center or one of our clinics.
All human subjects' research carried out at MercyOne Des Moines (or one of its clinics) is required to be reviewed by the IRB.
The IRB processes studies that are supported by industry and involve evaluation of a technology or product such as a drug, surgical procedure, medical device, diagnostic test or technique. Our clinical studies include Phase II – IV studies.
In order to determine whether your study will require full board review, can be expedited, or is exempt, contact The IRB Manager at irb@mercydesmoines.org for log-in information.
Listed below is the information that you will need to present your protocol to the Institutional Review Board. Remember, your presentation is a summary. You will want to keep the information short and the whole presentation around 10 minutes. You will need to present:
To submit a new study, please contact irb@mercydesmoines.org
MercyOne Des Moines Medical Center IRB now utilizes an online submission system (IRB Manager). You will need log-in information to access this system. This will be provided after you contact the IRB office at the email shown above.
What do I need to know about conflict of interest regarding my research?
Federal regulations and MercyOne policy require that investigators disclose any significant financial interests that may present an actual or potential conflict of interest in relationship to externally sponsored projects prior to initiation of the study. If you answer, “Yes” to any of the questions on the “Significant Financial Interests in a Sponsored Project – Addendum B” form you must reveal those financial interests on a separate submission before the protocol is reviewed by the full committee.
Federal Code Part 54 requires that investigators disclose financial interests in sponsors of clinical trials. Typically, the corporate sponsor will provide its own disclosure form which details what must be disclosed (royalties, patents, equity interest, etc.) The company’s disclosure form does not serve as a replacement or substitute for the MercyOne Financial Disclosure for, and the company’s form should be sent directly to the company, not to the IRB office.
“Investigator” means the principal investigator, co-investigator, and any other person at MercyOne Des Moines Medical Center who is responsible for the design, conduct, or reporting of research or educational activities funded, or proposed for funding, by an external sponsor. In this context, the term “Investigator” includes the investigator’s family (spouse, domestic partner, and dependent children).
Each investigator shall disclose all significant financial interests in the funding sponsor that would reasonably appear:
“Sponsor” means the organization or other entity providing funds.
“Significant financial interests” means anything of monetary value, including, but not limited to, salary or other payments for services (i.e. consulting fees or honoraria); equity interests (i.e. stocks, stock options, or other ownership interests); and intellectual property rights (i.e. patents, copyrights, and royalties from such rights). The term “significant financial interest” includes the following:
The term “significant financial interest” does not include the following:
The principal investigator is responsible for seeing that all investigators disclose their significant financial interest by completing and signing the “Significant Financial Interests in a Sponsored Project – Addendum B” form found with the application. The completed form(s) must be submitted with the Clinical Trial application. By signing the Clinical Trial application the principal investigator certifies that he/she has requested such information from all investigators.
Disclosure material will be considered confidential information to the extent permitted by law.